Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Acambis reports earnings, lowers guidance

Acambis (LSE:ACM; ACAM) reported second quarter revenues of L32.5 million ($58.4 million), down 20% from L40.5 million ($72.8 million) for the same period

Read the full 237 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE